Ernesto Muñoz

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

Hertzel C. Gerstein, Robert G. Hart, Helen M. Colhoun et al. · The Lancet Diabetes & Endocrinology · 2020 · 140 citations

Thrombosis, Rewind Trial, Ischemic Stroke +13

Neutrophilic eccrine hidradenitis in two neutropenic patients

F. Allegue, C. Soria, Antonio Rocamora et al. · Journal of the American Academy of Dermatology · 1990 · 39 citations

Neutropenic Patients, Histopathology, Pathology +2